Spinal Muscular Atrophy Market Growth (1) - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Spinal Muscular Atrophy Market Growth (1)

Description:

According to Renub Research forecast the global Spinal Muscular Atrophy Market to grow at a CAGR of 14% in the coming years. This high growth rate is primarily due to good reimbursement options in western countries, declining drug prices and projected launch of new drugs. One of the major growth drivers witnessing the growth of spinal muscular atrophy market is growing awareness of diagnosis and treatment of spinal muscular atrophy during the forecast period. For More Information: – PowerPoint PPT presentation

Number of Views:15

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Spinal Muscular Atrophy Market Growth (1)


1
Spinal Muscular Atrophy Market

2
Report Description and Highlights
Analyst View According to Renub Research
forecast the global Spinal Muscular Atrophy
Market to grow at a CAGR of 14 in the coming
years. This high growth rate is primarily due to
good reimbursement options in western countries,
declining drug prices and projected launch of new
drugs. Spinal muscular atrophy (SMA) is one of
the most common genomic disorders which are
caused due to the loss of specialized nerve cells
known as motor neurons in the brainstem and
spinal cord. The impairment of motor neurons
leads to the weakness and atrophy of muscles used
for the regular activities like crawling,
sitting, walking and the head movement. In worst
cases, the muscles used for breathing and
swallowing also get affected. On the basis of
severity of muscle weakness, the age of disease
commencement, there are four types of spinal
muscular atrophy namely type 1, type 2, type 3
and type 4. Type 1, 2 and 3 of spinal muscle
atrophy appears in childhood while type 4 appears
in adulthood.  One of the major growth drivers
witnessing the growth of spinal muscular atrophy
market is growing awareness of diagnosis and
treatment of spinal muscular atrophy during the
forecast period. The awareness about the spinal
muscular atrophy diagnosis and treatment is
growing among the patients.


3
Spinal Muscular Atrophy Market
Additionally, increasing government and
non-government support for the treatment and
diagnosis of spinal muscular atrophy further
boost the growth Global Spinal Muscular Atrophy
Market over the coming years. The government of
several countries across the world has developed
regulations to help medical professionals and
caregivers decide when to administer the cure
to the infants with spinal muscular atrophy. For
instance In 2018, the Canadian organization of
rare disorders signed a petition for funding
SPINRAZA for the treatment of Canadian patients
with spinal muscular atrophy. Spinal muscular
atrophy generally shows its symptoms in early
childhood and is a prime cause of mortality in
infants. According to Spinal Muscular Atrophy
(SMA) Foundation 2015 statistics, spinal muscular
atrophy has been affected nearly 10,000 to 25,000 
children and adults in the United States. Read
more here https//www.renub.com/spinal-muscular-
atrophy-market-p.php

4
Global Current Forecast for Spinal Muscular
Atrophy Patient Population Share
Global Current Forecast for Spinal Muscular
Atrophy Patient Population Share (Percent), 2017
2026

Source Renub Research Analysis Note These are
dummy figures actual data given in the report
5
Spinal Muscular Atrophy Market Summary
  • Market Summary
  • Country-wise, the report provides the Spinal
    muscular atrophy market and market share
    of United States, United Kingdom, France,
    Germany, Spain, Italy and Japan. 
  • Number of Patients-wise the report provides the
    total treated patients population and
    population share of United States, United
    Kingdom, France, Germany, Spain,
    Italy and Japan. 
  • Drug-wise, the report provides present and
    estimated global sales of Spinraza, AVXS-101,
    CK2127107, RG7916, Olesoxime LMI070.
  • Company-wise the report provides present and
    estimated global of Biogen Inc., Roche AG,
    Novartis AG andCytokinetics Inc.
  • Drugs Clinical Phase Study, The report provides
    113 Drugs clinical study pipeline status Which is
    at present, globally in the various stage such as
    (Phase I, II and III) unknown status, recruiting,
    active, not recruiting, terminated or completed
    stage.
  • Want more Information about this market? Request
    a free sample copy
  • https//www.renub.com/contactus.php


6
Forecast for Spinal Muscular Atrophy Market by
Drugs Sales
Forecast for Spinal Muscular Atrophy Market by
Drugs Sales 2017 2026

Source Renub Research Analysis Note These are
dummy figures actual data given in the report
7
Key Topics Covered in Spinal Muscular Atrophy
Market
  •    Introduction
  • 1.1    Market Definition 1.2    Currency
    Conversion
  • 2.    Research Methodology
  • 3.    Executive Summary
  • 4.    Global Spinal Muscular Atrophy Market and
    Patients Analysis
  • 4.1    Spinal Muscular Atrophy Market 4.2  
     Spinal Muscular Atrophy Patient Numbers4.3  
     Spinal Muscular Atrophy Treated Patient Number
  • 5.    Share Analysis Global Spinal Muscular
    Atrophy
  • 5.1    Country Market Share 5.2    Patients
    Population Share5.3    Treated Patients Share


8
Key Topics Covered in Spinal Muscular Atrophy
Market
6.    United States 6.1    Spinal Muscular
Atrophy Market 6.2    Spinal Muscular Atrophy
Patient Numbers6.3    Spinal Muscular Atrophy
Treated Patients 7.    United Kingdom 7.1  
 Spinal Muscular Atrophy Market 7.2    Spinal
Muscular Atrophy Patient Numbers7.3    Spinal
Muscular Atrophy Treated Patient Numbers 8.  
 Germany 8.1    Spinal Muscular Atrophy
Market 8.2    Spinal Muscular Atrophy Patient
Numbers8.3    Spinal Muscular Atrophy Treated
Patients 9.    Italy Spinal Muscular
Atrophy 9.1    Spinal Muscular Atrophy
Market 9.2    Spinal Muscular Atrophy Patient
Numbers9.3    Spinal Muscular Atrophy Treated
Patient Numbers

9
Key Topics Covered in Spinal Muscular Atrophy
Market
10.    France Spinal Muscular Atrophy 10.1  
 Spinal Muscular Atrophy Market 10.2    Spinal
Muscular Atrophy Patient Numbers10.3    Spinal
Muscular Atrophy Treated Patient Numbers 11.  
 Spain 11.1    Spinal Muscular Atrophy
Market 11.2    Spinal Muscular Atrophy Patient
Numbers11.3    Spinal Muscular Atrophy Treated
Patient Numbers 12.    Japan 12.1    Spinal
Muscular Atrophy Market 12.2    Spinal Muscular
Atrophy Patients12.3    Spinal Muscular Atrophy
Treated Patient Numbers 13.    Drugs Sales
Spinal Muscular Atrophy 13.1    Spinraza 13.2
   AVXS-10113.3    CK2127107 13.4  
 RG791613.5    Olesoxime 13.6    LMI070

10
Key Topics Covered in Spinal Muscular Atrophy
Market
14.    Spinal Muscular Atrophy Study Status
Analysis 14.1    Spinal Muscular Atrophy
Clinical Study 14.2    Spinal Muscular Atrophy
Drugs Development Pipeline 15.    Growth
Drivers 15.1    Increasing Funding for Research
Development15.2    Biogen Access Programs 16.
   Challenges. 16.1    High Treatment Cost 16.2
   Common Side Effects 17.    Biogen Inc. 17.1
   Business Overview 17.2    Initiatives/Strateg
ies17.3    Financial Insight

11
Key Topics Covered in Spinal Muscular Atrophy
Market
18.    Novartis AG 18.1    Business
Overview 18.2    Initiatives/Strategies18.3  
 Financial Insight 19.    Roche Holding AG 19.1
   Business Overview 19.2    Initiatives/Strateg
ies19.3    Financial Insight 20.  
 Cytokinetics, Inc. 20.1    Business
Overview 20.2    Initiatives/Strategies20.3  
 Financial Insight If the information you seek
is not included in the current scope of the study
kindly share your specific requirements with
our custom research team at info_at_renub.com

12
Key Topics Covered in Spinal Muscular Atrophy
Market
Browse Related Report Epilepsy Drugs
Market Allergic Conjunctivitis Market Contact
Us Tel 1-678-302-0700 (US), 91-120-421-9822
(INDIA) Email info_at_renub.com
About PowerShow.com